Figure 1
Figure 2
Figure 3
Maximum late side effects
| GI late | 0 | 1 | 2 | 3 | GU late | 0 | 1 | 2 | 3 |
|---|---|---|---|---|---|---|---|---|---|
| 78 Gy | 62% | 21% | 13% | 4% | 78 Gy | 49% | 23% | 23% | 5% |
| 74 Gy | 63% | 22% | 13% | 1% | 74 Gy | 53% | 21% | 22% | 3% |
| 66 Gy | 66% | 22% | 12% | 0% | 66 Gy | 54% | 29% | 15% | 2% |
Multivariate analysis of potential predictors of biochemical no evidence of disease (bNED)
| Variable | HR | 95% CI | p-value |
|---|---|---|---|
| iPSA (log2 transformed) | 1.193 | 1.058–1.345 | 0.004 |
| Gleason ≤ 6 or Histograding 1 | reference | ||
| Gleason 7 or Histograding 2 | 1.254 | 0.797–1.890 | 0.280 |
| Gleason 8-10 or Histograding 3 | 1.687 | 1.132–2.515 | 0.010 |
| Pelvic irradiation | 0.783 | 0.540–1.135 | 0.196 |
| T stage ≤ 2a | reference | ||
| T stage 2b/c | 1.466 | 0.950-2.262 | 0.084 |
| T stage 3/4 | 1.517 | 1.054-2.181 | 0.025 |
| Dose (Gy) | 0.928 | 0.890-0.969 | < 0.001 |
Maximum acute side effects
| GI acute | 0 | 1 | 2 | 3 | GU acute | 0 | 1 | 2 | 3 |
|---|---|---|---|---|---|---|---|---|---|
| 78 Gy | 11% | 50% | 39% | 1% | 78 Gy | 13% | 54% | 32% | 1% |
| 74 Gy | 35% | 35% | 29% | 1% | 74 Gy | 19% | 45% | 34% | 1% |
| 66 Gy | 38% | 22% | 40% | 0% | 66 Gy | 25% | 44% | 30% | 1% |
Patient characteristics
| Median Dose | 78 Gy | N = 141 | 74 Gy | N = 282 | 66 Gy | N = 142 |
|---|---|---|---|---|---|---|
| Dose distribution in Gy | ||||||
| Min | 76 | 70.4 | 60 | |||
| Max | 80 | 75 | 70 | |||
| N with median dose | 127 | 90% | 178 | 63% | 83 | 58% |
| T category | ||||||
| T1 | 43 | 30% | 48 | 17% | 21 | 15% |
| T2 | 61 | 43% | 108 | 38% | 53 | 37% |
| T3 | 36 | 26% | 121 | 43% | 60 | 42% |
| T4 | 1 | 1% | 5 | 2% | 8 | 6% |
| Gleason score | ||||||
| ≤6 or histological grading 1 | 20 | 14% | 94 | 31% | 40 | 11% |
| 7 or histological grading 2 | 29 | 21% | 66 | 20% | 52 | 4% |
| 8–10 or histol. grading 3 | 92 | 65% | 118 | 42% | 42 | 30% |
| X | 0 | 0% | 4 | 1% | 8 | 6% |
| iPSA in ng/ml | ||||||
| Median | 15.7 | 20.6 | 21 | |||
| Technique | ||||||
| 3D-conformal | 11 | 8% | 281 | 100% | 142 | 100% |
| IMRT or VMAT | 130 | 92% | 1 | 0% | 0 | 0% |
| Inclusion of LN | 133 | 94% | 105 | 37% | 15 | 11% |
| ADT | 126 | 89% | 259 | 92% | 113 | 80% |
| Mean in months | 21 | 16 | 23 | |||
| Follow-up in months | ||||||
| Min | 3 | 2 | 3 | |||
| Max | 116 | 240 | 240 | |||
| Median | 48 | 47 | 59 | |||
| Age in years | ||||||
| Min | 49 | 51 | 53 | |||
| Max | 84 | 86 | 93 | |||
| Median | 75 | 73 | 71 | |||
| Gold marker fiducials | 53% | 1% | 0% |